253 related articles for article (PubMed ID: 22112992)
21. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
22. Effect of cytomegalovirus immunoglobulin on the incidence of lymphoproliferative disease after lung transplantation: single-center experience with 1157 patients.
Jaksch P; Wiedemann D; Kocher A; Muraközy G; Augustin V; Klepetko W
Transplantation; 2013 Mar; 95(5):766-72. PubMed ID: 23364482
[TBL] [Abstract][Full Text] [Related]
23. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
[TBL] [Abstract][Full Text] [Related]
24. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
25. Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring.
Elidemir O; Kancherla BS; Schecter MG; McKenzie ED; Morales DL; Heinle JS; Mallory GB
Pediatr Transplant; 2009 Aug; 13(5):606-10. PubMed ID: 19017289
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study.
Lo RC; Chan SC; Chan KL; Chiang AK; Lo CM; Ng IO
J Clin Pathol; 2013 May; 66(5):392-8. PubMed ID: 23423516
[TBL] [Abstract][Full Text] [Related]
27. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
Quintini C; Kato T; Gaynor JJ; Ueno T; Selvaggi G; Gordon P; McLaughlin G; Tompson J; Ruiz P; Tzakis A
Transplant Proc; 2006; 38(6):1755-8. PubMed ID: 16908272
[TBL] [Abstract][Full Text] [Related]
28. Surgical management of gastrointestinal posttransplant lymphoproliferative disorders in liver transplant recipients.
Cruz RJ; Ramachandra S; Sasatomi E; DiMartini A; de Vera M; Fontes P; Hughes C; Humar A
Transplantation; 2012 Aug; 94(4):417-23. PubMed ID: 22820701
[TBL] [Abstract][Full Text] [Related]
29. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
[TBL] [Abstract][Full Text] [Related]
30. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.
Taylor AL; Bowles KM; Callaghan CJ; Wimperis JZ; Grant JW; Marcus RE; Bradley JA
Transplantation; 2006 Aug; 82(3):375-81. PubMed ID: 16906036
[TBL] [Abstract][Full Text] [Related]
31. Ultra-early onset post-transplantation lymphoproliferative disease.
Khedmat H; Taheri S
Saudi J Kidney Dis Transpl; 2013 Nov; 24(6):1144-52. PubMed ID: 24231475
[TBL] [Abstract][Full Text] [Related]
32. Incidence of post-transplantation lymphoproliferative disease in Andalusia (1990-2009).
Govantes MA; Esteve AF; Ramos MT; Gracia De Guindo MC; Sánchez LF; Blanca MA; Rodríguez-Benot A; Blandino MV; De la Nuez PC; Rodríguez DB
Transplant Proc; 2013; 45(10):3592-4. PubMed ID: 24314968
[TBL] [Abstract][Full Text] [Related]
33. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
[TBL] [Abstract][Full Text] [Related]
34. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
[TBL] [Abstract][Full Text] [Related]
35. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
36. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort.
Katz BZ; Pahl E; Crawford SE; Kostyk MC; Rodgers S; Seshadri R; Proytcheva M; Pophal S
Pediatr Transplant; 2007 Feb; 11(1):58-65. PubMed ID: 17239124
[TBL] [Abstract][Full Text] [Related]
37. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
38. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients.
Reams BD; McAdams HP; Howell DN; Steele MP; Davis RD; Palmer SM
Chest; 2003 Oct; 124(4):1242-9. PubMed ID: 14555552
[TBL] [Abstract][Full Text] [Related]
39. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
[TBL] [Abstract][Full Text] [Related]
40. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
